Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
18.50
-0.09 (-0.49%)
Nov 5, 2024, 1:15 PM EST - Market open
Capricor Therapeutics Employees
As of December 31, 2023, Capricor Therapeutics had 102 total employees, including 101 full-time and 1 part-time employees. The number of employees increased by 28 or 37.84% compared to the previous year.
Employees
102
Change (1Y)
28
Growth (1Y)
37.84%
Revenue / Employee
$266,198
Profits / Employee
-$273,986
Market Cap
841.24M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Aveanna Healthcare Holdings | 33,500 |
HealthStream | 1,092 |
Bioventus | 970 |
Cronos Group | 356 |
Prothena Corporation | 173 |
Pliant Therapeutics | 158 |
Pulse Biosciences | 56 |
Tyra Biosciences | 49 |
CAPR News
- 17 days ago - Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 19 days ago - Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock - GlobeNewsWire
- 19 days ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 25 days ago - Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - GlobeNewsWire
- 27 days ago - Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 4 weeks ago - Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - Benzinga
- 5 weeks ago - Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off - Seeking Alpha